Patent · US Active

RNA interference in dermal and fibrotic indications

US9963702B2 · kind B2 · utility

20Cited by

190References

20Claims

0Family size

Assignee

RXi Pharmaceuticals Corporation · US

Inventors

Anastasia Khvorova · Boulder, US
William Salomon · Worcester, US
Joanne Kamens · Newton, US
Dmitry Samarsky · Berlin, DE
Tod M. Woolf · Sudbury, US
Pamela Pavco · Longmont, US
Lyn Libertine · Framingham, US
James Cardia · Franklin, US
Karen G. Bulock · Mendon, US

Key dates

Filing date	Apr 14, 2016
Grant date	May 8, 2018
Priority date	—
Expiry date	Apr 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.